Nephron Research’s Liquid Biopsy Innovation Symposium – Key Themes and Takeaways

Nephron Research believes liquid biopsy represents a significant, untapped market for our coverage. Advances in science are opening several new clinical applications across cancer screening, minimal residual disease (MRD) testing and comprehensive genomic profiling (CGP).

To dig into these emerging themes further, Nephron analyst Jack Meehan convened our first Liquid Biopsy Innovation Symposium last Wednesday which featured leading experts debating clinical data, reimbursement and regulatory pathways to commercialization.  Our event featured 6 panels and included industry thought leaders from companies like Exact Sciences, Guardant Health, Natera and Biological Dynamics (private).

Following the symposium, Nephron analyst Jack Meehan published a lengthy report to subscribers including strategic and tactical takeaways for covered stocks EXAS, GH, and ILMN.  His report even included a summary of responses to our investor polling questions which provide an interesting view on sentiment for the space.   For more information on symposium takeaways, please contact